Schmid Summarizes Updates in HER2-Positive Breast Cancer Management


Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.

Welcome to OncLive On Air®! I’m your host today, Megan Hollasch.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Genentech, we had the pleasure of speaking with Peter Schmid, MD, PhD, FRCP.

Dr Schmid is the chair of Cancer Medicine, a professor of cancer medicine, and the centre lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute of Queen Mary University in London, England. He is also the clinical director of Barts Breast Cancer Centre at St Bartholomew’s Hospital.

Data from the 2023 San Antonio Breast Cancer Symposium included the phase 3 HER2CLIMB 02 trial (NCT03975647) findings, which revealed that the median time to disease progression or death was 9.5 months (95% CI, 7.4-10.9) for patients with advanced or metastatic HER2-positive breast cancer who were treated with ado-trastuzumab emtansine (T-DM1; Kadcyla) plus tucatinib (Tukysa) compared with 7.4 months (95% CI, 5.6-8.1) for patients given T-DM1 plus placebo; tucatinib plus T-DM1 reduced the risk of disease progression or death by 24% (HR, 0.77; 95% CI, 0.61-0.95; P = .0163).

In our exclusive interview, Dr Schmid discussed considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice and detailed how he treats patients with HER2-positive disease in differing settings.

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, sponsored by Genentech. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Content